DNDi E-news
February 2015   |   View Online

Will Crisis See a Long-Awaited Response to Lack of Innovation and Access Come from Public Leadership?


Viewpoint by Bernard Pécoul, Executive Director, DNDi

While the epidemic peak of the Ebola crisis slightly begins to wane and with it potential avenues for treatment beginning to emerge, the global health community simply cannot go back to business as usual. »

USAID awards its first-ever grant for NTD R&D to DNDi

With this USD 10 million grant from the United States Agency for International Development (USAID) in support of its filarial diseases programme, DNDi targets the development of new oral drugs for human river blindness (onchocerciasis) and elephantiasis (lymphatic filariasis). »

New agreement between Bayer and DNDi to test Emodepside for human river blindness

The molecule Emodepside, currently indicated for veterinary usage, will be provided by Bayer to DNDi to support its effort to develop a new oral drug to treat human river blindness. »

FDA Priority Review Voucher: Truly an incentive for R&D? Can it lead to patient access?

DNDi and MSF are asking these key questions about the FDA’s fast-track programme, following the award of a voucher for the leishmaniasis treatment Miltefosine last year. In a ‘Speaking of Medicine’ PLOS blog, DNDi and MSF call for a mechanism that ensures both patients and companies can win. »

Unique collection of articles on neglected infectious diseases in open access

The ‘Journal of Biomolecular Screening’ (JBS) released a special edition in collaboration with DNDi on the novel therapeutic approaches for neglected infectious diseases with comprehensive articles in immediate open access. »

Close up: Cutaneous leishmaniasis, a disfiguring neglected disease

DNDi travelled to Colombia to document cutaneous leishmaniasis (CL), which affects about 1 million people every year with disfiguring skin lesions and social stigma. »

Scientific Articles

Journal of Biomolecular Screening:
Repurposing of the Open Access Malaria Box for Kinetoplastid Diseases Identifies Novel Active Scaffolds against Trypanosomatids »

Journal of Medicinal Chemistry:
Novel 3-Nitrotriazole-Based Amides and Carbinols as Bifunctional Antichagasic Agents »

Journal of Biomolecular Screening:
Novel Therapeutic Approaches for Neglected Infectious Diseases »

Malaria Journal:
Fixed dose artesunate amodiaquine - a phase IIb, randomized comparative trial with non-fixed artesunate amodiaquine »

Strengthening neglected tropical disease research through enhancing research-site capacity: An evaluation of a novel web application to facilitate research collaborations »
Photo credits:
DNDi/Sylvain Cherkaoui, DNDi/Anita Khemka, DNDi/Fabio Nascimento
Punto de Vista: Bernard Pécoul »
Leishmaniasis cutánea o cómo una enfermedad no mortal puede ser una amenaza para la vida de las personas »

Ponto de Vista: Bernard Pécoul »
Leishmaniose cutânea: como uma doença não fatal pode ser uma ameaça à vida das pessoas »

Antimicrobial Resistance, Novel Drug Discovery and Development: Challenges and Opportunities
New Delhi, 2-3 March 2015

XI Workshop on Chagas Disease
Barcelona, 13 March 2015

GLOBVAC Conference 2015
Oslo, 17-18 March 2015

British Society of Parasitology Spring Meeting 2015
Liverpool,16-18 April 2015

Follow us on social media:
Twitter Facebook LinkedIn YouTube
Visit our websites:
DNDi.org  DNDiAL.org  DNDiNA.org  DNDiJapan.org  
Copyright © 2015 Drugs for Neglected Diseases initiative (DNDi), All rights reserved.
You are receiving this email because you are part of DNDi's network. You have the option to unsubscribe.

Our mailing address is:
Drugs for Neglected Diseases initiative (DNDi)
15 ch. Louis-Dunant
Geneva 1202

Add us to your address book

unsubscribe from this list    update subscription preferences